You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

240 Results
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Sep 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, according to clinical criteria
Jun 2023
Drug
Other Name(s): Onureg®
Aug 2023
Guidelines and Advice
Status: Current
ID: ES PET 20
Apr 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
New Drug Funding Program
    Atezolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer
Mar 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2023
Statistical Reports
Statistical Reports

Pages